Literature DB >> 28122174

Synthesis, QSAR studies, and metabolic stability of novel 2-alkylthio-4-chloro-N-(5-oxo-4,5-dihydro-1,2,4-triazin-3-yl)benzenesulfonamide derivatives as potential anticancer and apoptosis-inducing agents.

Beata Żołnowska1, Jarosław Sławiński1, Aneta Pogorzelska1, Krzysztof Szafrański1, Anna Kawiak2,3, Grzegorz Stasiłojć4, Mariusz Belka5, Joanna Zielińska5, Tomasz Bączek5.   

Abstract

A series of novel 2-alkylthio-4-chloro-N-(5-oxo-4,5-dihydro-1,2,4-triazin-3-yl)benzenesulfonamide derivatives 12-46 have been synthesized by the reaction of aminoguanidines with an appropriate alpha-oxo-acids hydrates in glacial acetic acid. All the synthesized compounds were evaluated for their anticancer activity against HeLa, HCT-116, and MCF-7 human tumor cell lines. Two compounds 33 and 34 displayed outstanding cytotoxic effect selectively toward HeLa cancer cells (IC50  = 19 μm) and did not exhibit toxicity to the non-cancerous HaCaT cells. QSAR analysis determined the most important parameters controlling cytotoxic activity of 5-oxo-1,2,4-triazines against HeLa cells. QSAR model showed five significant descriptors: HATS6s (GETAWAY descriptor), RDF125 m (radial distribution function), SpMax7_Bh(p) (Burden descriptor), SM3_G (3D matrix descriptor), and Hy (hydrophilic factor). The apoptotic potential of the most active compounds was thoroughly analyzed through various assays: cells' morphology, DNA fragmentation, mitochondrial potential disruption, and phosphatidylserine translocation. Selected compounds were tested for metabolic stability in the presence of pooled human liver microsomes and NADPH. Compound 34 was the most resistant for human metabolism (t1/2  = 38.5 min) and can be pointed as a hit compound for further investigations.
© 2017 John Wiley & Sons A/S.

Entities:  

Keywords:  QSAR; anticancer; apoptosis; benzenesulfonamide; metabolic stability; mitochondrial membrane potential; synthesis

Mesh:

Substances:

Year:  2017        PMID: 28122174     DOI: 10.1111/cbdd.12955

Source DB:  PubMed          Journal:  Chem Biol Drug Des        ISSN: 1747-0277            Impact factor:   2.817


  6 in total

1.  Modeling of Anticancer Sulfonamide Derivatives Lipophilicity by Chemometric and Quantitative Structure-Retention Relationships Approaches.

Authors:  Monika Pastewska; Beata Żołnowska; Strahinja Kovačević; Hanna Kapica; Maciej Gromelski; Filip Stoliński; Jarosław Sławiński; Wiesław Sawicki; Krzesimir Ciura
Journal:  Molecules       Date:  2022-06-21       Impact factor: 4.927

2.  Synthesis of 2-alkylthio-N-(quinazolin-2-yl)benzenesulfonamide derivatives: anticancer activity, QSAR studies, and metabolic stability.

Authors:  Aneta Pogorzelska; Beata Żołnowska; Jarosław Sławiński; Anna Kawiak; Krzysztof Szafrański; Mariusz Belka; Tomasz Bączek
Journal:  Monatsh Chem       Date:  2018-07-13       Impact factor: 1.451

3.  HATS5m as an Example of GETAWAY Molecular Descriptor in Assessing the Similarity/Diversity of the Structural Features of 4-Thiazolidinone.

Authors:  Mariusz Zapadka; Przemysław Dekowski; Bogumiła Kupcewicz
Journal:  Int J Mol Sci       Date:  2022-06-12       Impact factor: 6.208

4.  Synthesis, Molecular Structure, Anticancer Activity, and QSAR Study of N-(aryl/heteroaryl)-4-(1H-pyrrol-1-yl)Benzenesulfonamide Derivatives.

Authors:  Beata Żołnowska; Jarosław Sławiński; Zdzisław Brzozowski; Anna Kawiak; Mariusz Belka; Joanna Zielińska; Tomasz Bączek; Jarosław Chojnacki
Journal:  Int J Mol Sci       Date:  2018-05-16       Impact factor: 5.923

5.  Synthesis, Anticancer Evaluation and Structure-Activity Analysis of Novel (E)- 5-(2-Arylvinyl)-1,3,4-oxadiazol-2-yl)benzenesulfonamides.

Authors:  Krzysztof Szafrański; Jarosław Sławiński; Łukasz Tomorowicz; Anna Kawiak
Journal:  Int J Mol Sci       Date:  2020-03-23       Impact factor: 5.923

6.  Syntheses of Novel 4-Substituted N-(5-amino-1H-1,2,4-triazol-3-yl)pyridine-3-sulfonamide Derivatives with Potential Antifungal Activity.

Authors:  Krzysztof Szafrański; Jarosław Sławiński; Anna Kędzia; Ewa Kwapisz
Journal:  Molecules       Date:  2017-11-07       Impact factor: 4.411

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.